NEW YORK (360Dx) – Ceres Nanosciences said today it has received Breakthrough Device designation from the US Food and Drug Administration for its Lyme disease test.

The Breakthrough designation means FDA will work with Ceres to move the test from development to potential approval more quickly and at lower cost.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.